source
- FDA rejects Capricor’s Duchenne cell therapy after trials show no benefitThe Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…
- Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasisStakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…